Search

Your search keyword '"Papini, Anna Maria"' showing total 540 results

Search Constraints

Start Over You searched for: Author "Papini, Anna Maria" Remove constraint Author: "Papini, Anna Maria"
540 results on '"Papini, Anna Maria"'

Search Results

251. Cytotoxic glycosides from the roots of Weigela x "Bristol Ruby".

252. Role of Lipoylation of the Immunodominant Epitope of Pyruvate Dehydrogenase Complex: Toward a Peptide-Based Diagnostic Assay for Primary Biliary Cirrhosis

253. Design, synthesis, and conformational studies of [DOTA]‐Octreotide analogs containing [1,2,3]triazolyl as a disulfide mimetic.

255. Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae.

257. Optimization of peptide synthesis time and sustainability using novel eco-friendly binary solvent systems with induction heating on an automated peptide synthesizer.

258. Study of the Preparation and Properties of Chemically Modified Materials Based on Rapeseed Meal.

259. Triazole-Bridged Peptides with Enhanced Antimicrobial Activity and Potency against Pathogenic Bacteria.

260. A Promising Compound for Green Multiresponsive Materials Based on Acyl Carrier Protein.

261. The Role of the Unbinding Cycle on the Coordination Abilities of the Bi-Cyclopeptides toward Cu(II) Ions.

262. Influence of the modification of the cosmetic peptide Argireline on the affinity toward copper(II) ions.

263. Chemically modified antiviral peptides against SARS-CoV-2.

264. Upgrading of the general AMBER force field 2 for fluorinated alcohol biosolvents: A validation for water solutions and melittin solvation.

265. Peptide and peptidomimetic tyrosinase inhibitors.

266. Affinity Chromatography for Anti-Glucosylated Adhesin Antibody Purification: Depletion of Nonspecific Anti-Protein Antibodies and Antibody Recovery with Unconventional Elution Solutions.

267. Design, synthesis, conformational analysis, and biological activity of Cα 1 -to-Cα 6 1,4- and 4,1-disubstituted 1 H -[1,2,3]triazol-1-yl-bridged oxytocin analogues.

268. Tripeptides conjugated with thiosemicarbazones: new inhibitors of tyrosinase for cosmeceutical use.

269. Therapeutic applications of thymosin peptides: a patent landscape 2018-present.

270. Editorial: Women in chemistry 2022.

271. SARS-CoV-2 inhibitory activity of a short peptide derived from internal fusion peptide of S2 subunit of spike glycoprotein.

272. Glucopeptides derived from myelin-relevant proteins and hyperglucosylated nontypeable Haemophilus influenzae bacterial adhesin cross-react with multiple sclerosis specific antibodies: A step forward in the identification of native autoantigens in multiple sclerosis.

273. Chemoenzymatic Synthesis of Glycopeptides to Explore the Role of Mucin 1 Glycosylation in Cell Adhesion.

274. Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2.

275. Malaria vaccines.

276. Accelerated solid-phase synthesis of glycopeptides containing multiple N -glycosylated sites.

277. Porcine Relaxin but Not Serelaxin Shows Residual Bioactivity after In Vitro Simulated Intestinal Digestion-Clues for the Development of New Relaxin Peptide Agonists Suitable for Oral Delivery.

278. First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors.

279. Subcritical Hydrothermal Liquefaction as a Pretreatment for Enzymatic Degradation of Polyurethane.

280. Metal-Ion Interactions with Dodecapeptide Fragments of Human Cationic Antimicrobial Protein LL-37 [hCAP(134-170)].

281. Bicyclopeptides: a new class of ligands for Cu(II) ions.

282. Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design.

283. Role of Helical Structure in MBP Immunodominant Peptides for Efficient IgM Antibody Recognition in Multiple Sclerosis.

284. Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas.

285. Selective Capture of Anti-N-glucosylated NTHi Adhesin Peptide Antibodies by a Multivalent Dextran Conjugate.

286. A peptide-based anti-Adalimumab antibody assay to monitor immune response to biologics treatment in juvenile idiopathic arthritis and childhood chronic non-infectious uveitis.

287. ELISA based on peptide antigens reproducing cross-reactive viral epitopes to detect antibodies in latent autoimmune diabetes in adults vs. type 1 diabetes.

288. Peptides and Peptidomimetics as Inhibitors of Enzymes Involved in Fibrillar Collagen Degradation.

289. Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development.

290. Cross-reactive peptide epitopes of Enterovirus Coxsackie B4 and human glutamic acid decarboxylase detecting antibodies in latent autoimmune diabetes in adults versus type 1 diabetes.

291. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry.

292. Hyperglucosylated adhesin-derived peptides as antigenic probes in multiple sclerosis: Structure optimization and immunological evaluation.

293. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy.

294. Just a spoonful of sugar: Short glycans affect protein properties and functions.

295. A Photochromic Azobenzene Peptidomimetic of a β-Turn Model Peptide Structure as a Conformational Switch.

296. Glycoreplica peptides to investigate molecular mechanisms of immune-mediated physiological versus pathological conditions.

297. Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques.

298. Antibodies to post-translationally modified mitochondrial peptide PDC-E2(167-184) in type 1 diabetes.

299. Oleanane-type glycosides from the roots of Weigela florida "rumba" and evaluation of their antibody recognition.

300. Antibody Epitope of Human α-Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease.

Catalog

Books, media, physical & digital resources